Pharmaceuticals

Trastuzumab Biosimilars Market Insights On Growth Drivers, Trends, And Opportunities

May 4, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Large Will The Trastuzumab Biosimilars Market Be By 2030 Compared To Its 2026 Market Size?

The trastuzumab biosimilars market size has experienced substantial expansion in recent years. Its value is anticipated to rise from $6.9 billion in 2025 to $8.86 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 28.5%. The historical increase in this market can be attributed to factors like the elevated prevalence of HER2 positive breast cancer, the expiry of trastuzumab’s patent exclusivity, escalating costs of oncology medications, established regulatory avenues for biosimilars, and the integration of oncology care within hospitals.

The trastuzumab biosimilars market size is projected to experience rapid expansion over the upcoming years. By 2030, it is anticipated to reach $24.48 billion, demonstrating a compound annual growth rate (CAGR) of 28.9%. This anticipated growth during the forecast period stems from factors such as the increasing incidence of cancer, the broadening of indications to include gastric cancer, supportive reimbursement policies for biosimilars, enhanced trust among physicians, and intensified initiatives to control healthcare expenditures. Key trends observed within the forecast timeframe encompass the swift adoption of oncology biosimilars, enhanced availability of HER2-targeted treatments, competitive pricing within breast cancer therapy, broader application of oncology treatments in hospitals, and increasing willingness to switch to biosimilar alternatives.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3400&type=smp

What Major Factors Are Driving The Trastuzumab Biosimilars Market Forward?

The expansion of the trastuzumab biosimilars market has been fueled by an increase in the occurrence of breast and gastric cancer. Trastuzumab biosimilar is utilized in the management of human epidermal growth factor receptor 2 (HER2) overexpressing breast cancer and metastatic gastric cancer. For instance, in September 2023, the American Cancer Society, a US-based voluntary health organization dedicated to eliminating cancer, indicated that approximately 297,790 new cases of invasive breast cancer are anticipated to be diagnosed in women in 2023, and about 43,700 women are expected to die from breast cancer in the same year. According to Cancer India, breast cancer is the most common cancer among women in India, making up 14% of all cancers in women. Therefore, the rising prevalence of breast and gastric cancer drives the demand for trastuzumab biosimilar, offering a cost-effective alternative to expensive medicines, consequently boosting the trastuzumab biosimilars market.

What Are The Key Segment Divisions In The Trastuzumab Biosimilars Market Segment Structure?

The trastuzumab biosimilars market covered in this report is segmented –

1) By Product: Ogivri, Herzuma, Ontruzant, Trazimera, Other Products

2) By Indication: Adjuvant Breast Cancer, Metastatic Breast Cancer, Metastatic Gastric Cancer, Other Indications

3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy

What Trends Are Affecting The Growth Of The Trastuzumab Biosimilars Market?

Key industry participants are consistently prioritizing the introduction of novel offerings in previously unexplored geographical areas, thereby influencing the landscape of the trastuzumab biosimilars market. Entities engaged in the trastuzumab biosimilars market are undertaking diverse strategic measures, including the creation of new products, collaborations, and an expansion of their regional presence and product range, all aimed at preserving their market competitiveness and more effectively addressing customer requirements. An example of this is Accord BioPharma Inc., a pharmaceutical firm based in the US, which revealed in April 2024 that the U.S. Food and Drug Administration (FDA) had granted approval for HERCESSI (trastuzumab-strf). This product is a biosimilar to Herceptin (trastuzumab), designated for the Treatment of Several Forms of HER2-Overexpressing Cancer. HERCESSI’s indications include the adjuvant therapy for HER2-overexpressing breast cancer, metastatic breast cancer, and metastatic gastric or gastroesophageal junction adenocarcinoma. While HER2-positive cancers typically exhibit aggressive characteristics, they demonstrate good responsiveness to targeted therapeutic interventions. The mechanism of action for HERCESSI involves attaching to the HER2 receptor, which in turn hinders its function and consequently decelerates the proliferation of cancer cells.

Which Organizations Are Engaged In The Trastuzumab Biosimilars Market?

Major companies operating in the trastuzumab biosimilars market are Pfizer Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Mylan NV, Fujifilm Kyowa Kirin Biologics Co. Ltd., Innovent Biologics Inc., STADA Arzneimittel AG, Apotex Inc., Samsung Bioepis Co. Ltd., Celltrion Inc., Zydus Lifesciences Limited, BIOCAD, Shanghai Henlius Biotech Inc., Biocon Limited, Alvotech Holdings S.A., Polpharma Biologics S.A, EirGenix Inc., Hetero Biopharma Limited, Mabion SA, ALTEOGEN Inc., Prestige BioPharma Limited, AryoGen Pharmed Co. Ltd., Intas Pharmaceuticals Limited, Glenmark Pharmaceuticals Ltd., Dr. Reddy’s Laboratories Limited, Torrent Pharmaceuticals Limited

Get The Full Trastuzumab Biosimilars Market Report:

https://www.thebusinessresearchcompany.com/report/trastuzumab-biosimilar-global-market-report

Which Region Is The Leading Market For The Trastuzumab Biosimilars Market?

North America was the largest region in the trastuzumab biosimilars market in 2025. Middle East is expected to be the fastest growing region in the trastuzumab biosimilars market report during the forecast period. The regions covered in the trastuzumab biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Trastuzumab Biosimilars Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/trastuzumab-biosimilar-global-market-report

Browse Through More Reports Similar to the Global Trastuzumab Biosimilars Market 2026, By The Business Research Company

Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Oncology Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/oncology-biosimilar-global-market-report

Oral Biologics And Biosimilars Market 2026

https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilars-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795